Article Data

  • Views 310
  • Dowloads 129

Case Reports

Open Access

A sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma: a case report

  • M. Dede1
  • K. Gezginç1,*,
  • I·. Alanbay1
  • U. Fidan1
  • M. Yenen1

1Department of Obstetrics and Gynecology, Gulhane Military Medical Academy, Ankara, Turkey

DOI: 10.12892/ejgo200802193 Vol.29,Issue 2,March 2008 pp.193-195

Published: 10 March 2008

*Corresponding Author(s): K. Gezginç E-mail:

Abstract

A rare case of a patient with a histopathological diagnosis of a sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma is reported. A 52-year-old patient was referred to our clinic for an adnexal mass. At pelvic examination, an irregular, fixed, approximately 7-8 cm in size mass was detected in the right adnexal area. At transvaginal ultrasonographic examination, it was observed that there was an 80 x 70 mm sized, irregularly contoured, semisolid mass with hyper-echogenous areas inside originating from the ovary in the right adnexal area. At laboratory examination tumor marker CA-125 was 280.4 U/ml (< 35), CA-15-3 was 146.5 U/ml (< 25), whereas other markers were within normal range. The patient was operated on for a right adnexal mass. A staging laparatomy procedure was applied. Postoperative histopathological diagnosis was reported as malignant mixed mullerian tumor of the ovary, with the ovarian component as poorly differentiated adenocarcinoma, and the metastatic foci over serosal surfaces as a sarcomatous component. Postoperatively six courses of adjuvant and consolidation chemotherapy were administered to the patient. Further studies are needed to set a consensus about evaluation of treatment and prognosis for this kind of pathology.

Keywords

Ovarian malign mixed mullerian tumor; Peritoneal implant; Treatment

Cite and Share

M. Dede,K. Gezginç,I·. Alanbay,U. Fidan,M. Yenen. A sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma: a case report. European Journal of Gynaecological Oncology. 2008. 29(2);193-195.

References

[1] Wei L.H., Huang C.Y., Cheng S.P., Chen C.A., Hsieh C.Y.: “Carcinosarcoma of ovary associated with previous radiotherapy”. Int. J. Gynecol. Cancer, 2001, 11, 81.

[2] Ariyoshi K., Kawauchi S., Kaku T., Nakano H., Tsuneyoshi M.: “Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases”. Histopathology, 2000, 37, 427.

[3] Muntz H.G., Jones M.A., Goff B.A. et al.: “Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy”. Cancer, 1995, 76, 1209.

[4] Bicher A., Levenback C., Silva E.G., Burke T.W., Morris M., Gershenson D.M.: “Ovarian malignant mixed mullerian tumors treated with platinum- based chemotherapy”. Obstet. Gynecol., 1995, 85, 735.

[5] Gallardo A., Matias-Guiu X., Lagarda H. et al.: “Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases”. Int. J. Gynecol. Pathol., 2002, 21, 268.

[6] Scully R.E., Young R.H., Clement P.B.: “Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament”. In: Rosai J. (ed.). Atlas of Tumor Pathology, 3rd series, fascicle 23 Washington, DC: Armed Forces Institute of Pathology, 1998, 128.

[7] Hellstrom A.C., Tegerstedt G., Silfversward C., Pettersson F.: “Malignant mixed mullerian tumors of the ovary: histopathologic and clinical review of 36 cases”. Int. J. Gynecol. Cancer, 1999, 9, 312.

[8] Bicher A., Levenback C., Silva EG., Burke T.W., Morris M., Gershenson D.M.: “Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy”. Obstet. Gynecol. 1995, 85, 735.

[9] Baker TR., Piver MS., Caglar H., Piedmonte M.: “Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary”. Am. J. Clin. Oncol., 1991, 9, 246.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top